Author:
Leclercq Mathilde,Goupillou Paul,Gomez Hélène,Muraine Marc,Benhamou Ygal,Girszyn Nicolas,Gueudry Julie
Abstract
Abstract
Purpose
The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available.
Results
We report a case series of patients with chronic noninfectious uveitis with incomplete efficacy of subcutaneous tocilizumab, improved after switching to intravenous routes. Improvement of visual acuity was observed with intravenous tocilizumab for all patients. Half of the patients could stop corticosteroids. Rapid efficacy of intravenous tocilizumab was observed, between 2 and 3 months.
Conclusion
In uveitis, tocilizumab administration could be optimized by a switching from a subcutaneous to an intravenous administration route.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Ophthalmology
Reference12 articles.
1. Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D et al (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73:69–74
2. Vegas-Revenga N, Calvo-Río V, Mesquida M, Adán A, Hernández MV, Beltrán E et al (2019) Anti-il6-r tocilizumab in refractory and non-infectious uveitic cystoid macular edema. Multicenter study of 25 patients. Am J Ophthalmol 200:85–94
3. Mesquida M, Molins B, Llorenç V et al (2018) Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina Phila Pa 38:1361–1370
4. Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P et al (2017) Primary (Month-6) Outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with non-infectious uveitis. Am J Ophthalmol 183:71–80
5. Pépin F, Niederer RL (2022) Re: Leclercq et al.: Anti-tumor necrosis factorα versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network. Ophthalmology S0161–6420(22):00158–0
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Mutilple drugs;Reactions Weekly;2024-07-20